ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

Learn More

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

Learn More

TheraSilence™

Using systemic RNAi delivery to fight and prevent tumor growth

Learn More

Novel approaches to enhance the power of proven chemotherapy, immunotherapy, and RNAi agents

Learn More

ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

Learn More

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

Learn More

TheraSilence™

Using systemic RNAi delivery to fight and prevent tumor growth

Learn More

Novel approaches to enhance the power of proven chemotherapy, immunotherapy, and RNAi agents

Learn More

ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

Learn More

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

Learn More

TheraSilence™

Using systemic RNAi delivery to fight and prevent tumor growth

Learn More

Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments

With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®,  a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer, and in the EU-DIGNITY Study, a phase 2 clinical trial for the treatment of recurrent chest wall breast cancer (RCW). Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase 1 OVATION Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.

TECHNOLOGY

Platform technologies designed to fight and prevent tumor growth

Read More

PRODUCTS

Enhancing clinically proven agents in chemotherapy and immunotherapy

Read More

PIPELINE

A well-balanced portfolio of preclinical through phase 3 clinical studies

Read More

Pipeline of Targeted Therapeutic Agents

News & Events

Share This